Kerala Ayurveda Limited gains Bali control, keeps 50% stake
Key highlights
- Nutraveda can appoint 2 of PT KAB’s 3 directors from October 29, 2026.
- Nutraveda’s equity holding in PT KAB remains unchanged at 50%.
- KAL said no consideration or acquisition cost was payable for the control acquisition.
- PT KAB was incorporated on October 30, 2025 and reported nil turnover.
powered by IRIS

Kerala Ayurveda Limited gained control of PT Kerala Ayurveda Bali, Indonesia, effective October 29, 2026, after its wholly owned subsidiary received the right to appoint two of the venture’s three directors while retaining a 50% equity stake and paying no consideration. The board rights, rather than additional shares, made PT KAB a subsidiary of KAL.
Know Kerala Ayurveda inside out
Results, valuation, peers and who's buying, in one view.
How did KAL gain control of its Bali joint venture?
KAL gained control through a majority board-appointment right, not through buying shares. Nutraveda Pte. Ltd., Singapore, KAL’s wholly owned subsidiary, received the right to appoint two of the three directors of PT KAB under a Novation and Addendum executed on October 29, 2026. That right gives Nutraveda control of the three-member board.
PT KAB consequently became a step-down subsidiary of KAL from October 29, 2026. The filing describes PT KAB as a joint venture between Nutraveda and Ms. Monica Mohindra, each of whom holds 50% of its equity share capital. The change therefore shifts control of the Indonesia-based Ayurveda wellness and resort venture through governance rights while leaving its capital ownership structure unchanged.
The new arrangement follows KAL’s September 20, 2022 Memorandum of Understanding, or MoU, with Mr. Arvind Mohindra regarding the Ayurvedagram Bali initiative. Under the October 29, 2026 Novation and Addendum, KAL’s rights and obligations under the MoU moved to Nutraveda, while Mr. Arvind Mohindra’s rights and obligations were novated or assigned to Ms. Monica Mohindra.
Did KAL buy more shares in PT KAB?
No, KAL did not acquire additional shares in PT KAB because Nutraveda continues to hold 50% of the venture. Ms. Monica Mohindra also continues to hold 50%, according to the disclosure. The transaction changed control rights, rather than the proportion of equity held by either joint-venture partner.
KAL said no consideration was payable for the acquisition of control. The filing records cash consideration, share swap, acquisition cost and acquisition price as not applicable, because no shares were acquired. Nutraveda instead obtained two of three board appointments, equivalent to a majority of the seats on PT KAB’s board.
This distinction is material to the structure disclosed by KAL. Nutraveda has an unchanged equal economic stake in PT KAB but now has a majority of board appointments. KAL holds 100% of Nutraveda, which is why Nutraveda’s board-control right results in PT KAB becoming a subsidiary within KAL’s group.
What does the Novation and Addendum change for KAL?
The Novation and Addendum moves the original MoU rights and obligations from KAL to Nutraveda and records PT KAB’s revised governance. KAL said it is fully released from obligations under the original MoU going forward. The agreement also transfers the rights and obligations of Mr. Arvind Mohindra to Ms. Monica Mohindra.
The original MoU was dated September 20, 2022, and KAL had announced the Ayurvedagram Bali initiative on December 14, 2022. Nutraveda subsequently entered a joint-venture arrangement with Ms. Monica Mohindra, leading to PT KAB’s incorporation on October 30, 2025. KAL disclosed that 50:50 joint-venture structure to the exchange on December 27, 2025.
KAL classified the arrangement as a related-party transaction because PT KAB is a joint venture of Nutraveda, its wholly owned subsidiary. The company said the transaction was in the ordinary course of business and on an arm’s-length basis. Mr. Ramesh Vangal, Chairman and Non-Executive Director of KAL, is a nominee director of Nutraveda on PT KAB’s board.
The filing identifies the parties to the new agreement as Nutraveda, Ms. Monica Mohindra and PT KAB. It says the purpose was to novate KAL’s MoU rights and obligations to Nutraveda and document governance of PT KAB. KAL did not disclose any fresh share issue, subscription right or restriction on PT KAB’s capital structure in connection with the amendment.
Got a follow-up? Ask IRIS
What business and turnover does PT KAB have?
PT KAB operates in Ayurveda wellness and resorts in Indonesia, and it reported nil turnover in KAL’s disclosure. The filing lists its business as Ayurveda wellness and resort, its country of presence as Indonesia, and its turnover history for the last three years as nil.
PT KAB was incorporated in Indonesia on October 30, 2025. Compared with the December 27, 2025 disclosure of a 50:50 joint venture, the October 29, 2026 arrangement adds majority board control for Nutraveda. The filing provides no operating revenue, profit, asset value, investment amount or segment contribution for PT KAB beyond the nil turnover figure.
KAL’s disclosure describes the objective and impact of the control acquisition as obtaining the right to appoint a majority of PT KAB’s directors. It specifies that there will be no change in PT KAB’s shareholding pattern. The filing therefore supports a governance change in an entity operating in the Ayurveda wellness and resort business, rather than an expansion of Nutraveda’s ownership percentage.
When did KAL disclose the Bali control arrangement?
KAL disclosed the arrangement on November 18, 2026, after receiving copies of the executed October 29, 2026 document on November 17, 2026. The company said it made the disclosure after receiving and verifying the Novation and Addendum, and described the delay as inadvertent and regretted.
The disclosure was made under Regulation 30 of the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations, 2015. KAL also submitted acquisition-of-control and agreement-amendment disclosures under the Securities and Exchange Board of India Master Circular dated January 30, 2026. The control acquisition remained effective from October 29, 2026 despite the later receipt of signed copies.
KAL stated that no governmental or regulatory approvals are required in India. Indonesian corporate filings will be made as applicable, but the filing does not provide a completion date for those filings. It also does not state any plan to increase Nutraveda’s 50% equity stake, provide additional capital, or set a revenue target for PT KAB.
Conclusion
KAL has converted PT KAB from a 50:50 joint venture into a subsidiary through Nutraveda’s right to appoint two of three directors. The effective date was October 29, 2026, no consideration was payable, and Nutraveda’s 50% shareholding remains unchanged. The disclosed change is therefore control through board governance rather than an equity acquisition.
The next disclosed matter to watch is the completion of Indonesian corporate filings as applicable. KAL has not disclosed a timetable for those filings, a further investment plan, a shareholding increase, or financial targets for PT KAB, which reported nil turnover and was incorporated on October 30, 2025.


